Screener / SEC EDGAR /CIK 0001582313 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Xenon Pharmaceuticals Inc. XENE

Compare with peers Embed
Planned sales, announced before they happen

0 trading plans running, 15 Form 144 notices for $22.0M

10-Q, 10-K and Form 144

What XENE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Aug 15, 2025 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Andrea DiFabio
Chief Legal Officer
Adopted 10b5-1 plan Jun 30, 2026 10-Q Aug 6, 2026
Ian Mortimer
President and Chief Executive Officer and a member of the Board of Directors
Ended 10b5-1 plan Jun 30, 2026 10-Q Nov 12, 2024
Dr. Christopher Kenney
Chief Medical Officer
Adopted 10b5-1 plan May 29, 2026 10-Q Aug 6, 2026
Andrea DiFabio
Chief Legal Officer and Corporate Secretary
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 26, 2026
Christopher Kenney
Chief Medical Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 26, 2026
Darren Cline
Chief Commercial Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 26, 2026
Ian Mortimer
President and Chief Executive Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 26, 2026
Thomas P. Kelly
Chief Financial Officer
Adopted 10b5-1 plan Dec 3, 2025 10-K Feb 26, 2026
Dr. Gary Patou
Board of Directors
Adopted 10b5-1 plan Aug 17, 2025 10-Q Nov 3, 2025
Dr. Gillian Cannon
Board of Directors
Adopted 10b5-1 plan Aug 15, 2025 10-Q Nov 3, 2025
Ian Mortimer
President and Chief Executive Officer
Adopted plan – 10-Q Nov 9, 2026
Thomas P. Kelly
Chief Financial Officer
Adopted plan – 10-Q Nov 9, 2026
Show the other 4 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Aug 28, 2026 CHRISTOPHER KENNEY
Officer
7,068 $438K
Aug 13, 2026 STEVEN GANNON
Director
10,000 $641K
Jun 5, 2026 GILLIAN CANNON
Director
1,190 $63K
Jun 5, 2026 GARY PATOU
Director
1,322 $70K
Mar 13, 2026 CHRISTOPHER JOHN KENNEY
Officer
1,410 $78K
Mar 13, 2026 ANDREA DIFABIO
Officer
1,342 $74K
Mar 13, 2026 IAN MORTIMER
Officer, Director
7,308 $404K
Mar 10, 2026 ANDREA DIFABIO
Officer
2,607 $157K
Mar 10, 2026 CHRISTOPHER JOHN KENNEY
Officer
2,771 $167K
Mar 10, 2026 IAN MORTIMER
Officer, Director
11,269 $677K
Mar 9, 2026 IAN MORTIMER
Officer, Director
270,000 $16.3M
Jan 2, 2026 IAN MORTIMER
Officer, Director
40,000 $1.8M
Dec 8, 2025 IAN MORTIMER
Officer, Director
10,830 $495K
Dec 5, 2025 IAN MORTIMER
Officer, Director
14,375 $647K
Dec 1, 2025 IAN MORTIMER
Officer, Director
97 $4K
Show the other 7 notices

From the Form 144 XML filed with the SEC, since Dec 1, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.